BioSpace News Archive

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental Biologics License Application (sBLA) for VAXNEUVANCE.

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), today announced that it has been granted United States Patent No. 11,185,523, “Use of Bipolar Trans Carotenoids With Chemotherapy and Radiotherapy for Treatment of Cancer,” by the United States Patent and Trademark Office.

Molecular Targeting Technologies, Inc. (MTTI) and Evergreen Theragnostics, Inc., today announced an agreement in which Evergreen will manufacture MTTI’s EvaThera™ platform of radiopharmaceuticals.

LintonPharm Co., Ltd. today announced that the first patient has been dosed in the Company’s Phase 1/2 clinical trial program for catumaxomab.

IQVIA recognized in IDC MarketScape™ for its data and analytics capabilities and growing suite of software platforms.

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced the completion of enrolment for DISSOLVE I, the first of two clinical studies of the phase 3 DISSOLVE development programme of SEL-212 for chronic refractory gout.

Akari Therapeutics, Plc announces data from observational studies in COVID pneumonia and chronic obstructive pulmonary disease that highlight the potential role of complement and leukotriene hyperactivity in driving life threatening disease exacerbations and therefore a potential therapeutic role for nomacopan.

Regulus Therapeutics Inc. today announced a presentation at the first annual Rare & Genetic Kidney Disease Drug Development Summit.

Relmada Therapeutics, Inc. announced today that the data related to the recently completed human abuse potential (HAP) study evaluating REL-1017—the company’s lead product candidate—versus oxycodone, will be presented in a poster presentation at the 60th Annual Meeting of the American College of Neuropsychopharmacology, which is taking place December 5-8, 2021, in San Juan, Puerto Rico.

NEOGEN Corporation announced that it has acquired Delf Ltd., a United Kingdom-based manufacturer and supplier of animal hygiene and industrial cleaning products.